The SENTRY Clinical Study

This study is not yet open for participant recruitment. (see Contacts and Locations)
Verified January 2014 by Novate Medical
Sponsor:
Information provided by (Responsible Party):
Novate Medical
ClinicalTrials.gov Identifier:
NCT01975090
First received: October 28, 2013
Last updated: January 3, 2014
Last verified: January 2014
  Purpose

The SENTRY Bioconvertible Inferior Vena Cava (IVC) Filter has been developed to provide temporary protection against pulmonary embolism (PE).


Condition Intervention
Pulmonary Embolism
Deep Vein Thrombosis
Device: SENTRY IVC Filter

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Prospective, Multi-Center Study of the Novate Sentry Bioconvertible Vena Cave Filter

Resource links provided by NLM:


Further study details as provided by Novate Medical:

Primary Outcome Measures:
  • Clinical Success Rate of the Sentry IVC Filter [ Time Frame: 6 Months ] [ Designated as safety issue: Yes ]

    A Composite Endpoint including:

    Technical success in deployment without acute Events; Freedom from Symptomatic Pulmonary Embolism; and Freedom from IVC filter related complications



Secondary Outcome Measures:
  • (1) Technical Success (2) Filter Status (3) Symptomatic PE (4) Freedom from IVC filter related complications [ Time Frame: 1, 2, 6 and 12 Months ] [ Designated as safety issue: Yes ]
    IVC filter related complications include, filter tilting, migration, embolization, fracture, vessel perforation, symptomatic caval thrombosis, invasive filter intervention and filter-related death.


Other Outcome Measures:
  • (1) New Symptomatic DVT(5) Procedure related serious adverse events (SAE) (2) New or symptomatic venous thromboembolism [ Time Frame: 1, 2, 6 and 12 Months ] [ Designated as safety issue: Yes ]

Estimated Enrollment: 135
Study Start Date: November 2013
Estimated Study Completion Date: June 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: SENTRY IVC Filter
The SENTRY IVC Bioconveretible Filter
Device: SENTRY IVC Filter
The SENTRY IVC Bioconvertible Filter is designed to provide temporary protection to subjects at transient, high risk of pulmonary embolism. Following conclusion of the protection period The SENTRY filter bioconverts, and filter arms withdraw towards the IVC wall for incorporation; obviating the need for retrieval.

Detailed Description:

Pulmonary embolism (PE) is a prevalent disease with a significant morbidity and mortality. The estimated annual incidence is 1.45 per 1,000 patients, which translates to 1,350,000 cases per year in the United States. It is estimated that PE results in more than 200,000 deaths per year.

Currently there are two types of commercially available IVC filters utilized to prevent PE; permanent and retrievable. Both types of filters have documented limitations, such as tilting, migration, fracture, embolization and late deep vein thrombosis (DVT). Retrievable filters were developed to avert some of the late consequences of permanent filter, but in practice there is low success with eventual removal. In a series of 37 clinical studies, with a total of 6,834 patients the mean retrieval rate was 34%.

There are numerous design features of the SENTRY IVC Filter that are intended to improve on the limitations of available IVC filters and obviate the need for retrieval.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. > 18 years of age
  2. fully informed subject who has executed an Institutional Review Board (IRB) or Ethics Committee (EC) approved informed consent
  3. willing and able to comply with follow-up visit requirements
  4. requirement of transient PE protection of < 60 days
  5. documented or high risk of PE or DVT
  6. inability to use anti-coagulation due to contraindication, failure, complication or risk of injury from pharmacotherapy
  7. IVC diameter compatible with filter diameter
  8. IVC length adequate for filter placement

Exclusion Criteria:

  1. intellectual impairment preventing understanding involvement in a clinical study
  2. hypersensitivity to device components
  3. impaired renal function defined as a serum creatinine level of > 2.0 mg/dL
  4. active systemic infection
  5. life expectancy < 12 months
  6. malignancy extending PE risk > 60 days
  7. pregnant or plans to become pregnant during study follow-up period
  8. participating in another investigational trial that has not reached its primary endpoint
  9. known hypercoaguable state
  10. inherited or acquired hemostatic disorder
  11. history or presence of a caval stent or filter
  12. inability to gain femoral or jugular access
  13. duplicated or left sided IVC
  14. renal vein thrombosis or IVC thrombosis extending to the renal veins
  15. jugular and femoral vein irregularity, stenosis or aneurysm that would interfere with successful device delivery
  16. spinal irregularity that may interfere with successful device delivery
  17. occlusive or free-floating thrombus in the IVC
  18. contrast allergy that cannot be adequately pre-medicated
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01975090

Contacts
Contact: Dennis P. McHugh, MS +1-925-558-2642 dennis.mchugh@novate.biz

  Hide Study Locations
Locations
United States, Alabama
University of Alabama Not yet recruiting
Birmingham, Alabama, United States, 35294
United States, California
Cedars Sinai Hospital Not yet recruiting
Los Angeles, California, United States, 90048
Stanford Hospital & Clinic Not yet recruiting
Palo Alto, California, United States, 94305
United States, Connecticut
Hartford Hospital Not yet recruiting
Hartford, Connecticut, United States, 06108
United States, Delaware
Christiana Hospital Not yet recruiting
Newark, Delaware, United States, 19718
United States, Florida
University of Florida Not yet recruiting
Gainesville, Florida, United States, 32610
University of Florida/ Shands Jacksonville Medical Center Not yet recruiting
Jacksonville, Florida, United States, 32209
Tampa General Hospital Not yet recruiting
Tampa, Florida, United States, 33603
United States, Georgia
Emory University Not yet recruiting
Atlanta, Georgia, United States, 30322
United States, Illinois
Adventist Midwest Health Not yet recruiting
Hinsdale, Illinois, United States, 60521
St. Francis Hospital Not yet recruiting
Peoria, Illinois, United States, 61603
United States, Indiana
Indiana University Not yet recruiting
Indianapolis, Indiana, United States, 46202
United States, Massachusetts
Massacusetts General Hospital Not yet recruiting
Boston, Massachusetts, United States, 02114
United States, Missouri
Washington University in St Louis Not yet recruiting
St. Louis, Missouri, United States, 63110
United States, North Carolina
University of North Carolina Not yet recruiting
Chapel Hill, North Carolina, United States, 27599
Rex Hospital Not yet recruiting
Raleigh, North Carolina, United States, 27607
United States, Ohio
Riverside Methodist Hospital Not yet recruiting
Columbus, Ohio, United States, 43214
Jobst Vascular Institute Recruiting
Toledo, Ohio, United States, 43606
United States, Rhode Island
Rhode Island Hospital Not yet recruiting
Providence, Rhode Island, United States, 02903
United States, Texas
University of Texas Southwestern Not yet recruiting
Dallas, Texas, United States, 75390
Belgium
Imelda Hospital Not yet recruiting
Bonheiden, Belgium
AZ Sint-Blasius Not yet recruiting
Dendermonde, Belgium
Chile
Pontificia Universidad Catolica De Chile Recruiting
Santiago, Chile
Sponsors and Collaborators
Novate Medical
Investigators
Principal Investigator: Michael D Dake, MD Stanford University
  More Information

Publications:
Responsible Party: Novate Medical
ClinicalTrials.gov Identifier: NCT01975090     History of Changes
Other Study ID Numbers: CI 036
Study First Received: October 28, 2013
Last Updated: January 3, 2014
Health Authority: United States: Food and Drug Administration
Chile: Institutional Review Board
Belgium: Agence fédérale des médicaments et des produits de santé

Additional relevant MeSH terms:
Embolism
Pulmonary Embolism
Thrombosis
Venous Thrombosis
Embolism and Thrombosis
Vascular Diseases
Cardiovascular Diseases
Lung Diseases
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on July 28, 2014